Spyre Therapeutics Statistics
Share Statistics
Spyre Therapeutics has 60.35M
shares outstanding. The number of shares has increased by 18.66%
in one year.
| Shares Outstanding | 60.35M |
| Shares Change (YoY) | 18.66% |
| Shares Change (QoQ) | 2.64% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 149 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 12.55M, so 20.83% of the outstanding
shares have been sold short.
| Short Interest | 12.55M |
| Short % of Shares Out | 20.83% |
| Short % of Float | 26.75% |
| Short Ratio (days to cover) | 21.38 |
Valuation Ratios
The PE ratio is -41.9 and the forward
PE ratio is -4.57.
Spyre Therapeutics's PEG ratio is
0.42.
| PE Ratio | -41.9 |
| Forward PE | -4.57 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 16.83 |
| P/FCF Ratio | -55.37 |
| PEG Ratio | 0.42 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Spyre Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.26,
with a Debt / Equity ratio of 0.
| Current Ratio | 11.26 |
| Quick Ratio | 11.26 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,849,561.64 |
| Employee Count | 73 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 51K |
| Effective Tax Rate | -0.02% |
Stock Price Statistics
The stock price has increased by -54.34% in the
last 52 weeks. The beta is 2.79, so Spyre Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.79 |
| 52-Week Price Change | -54.34% |
| 50-Day Moving Average | 14.93 |
| 200-Day Moving Average | 23.52 |
| Relative Strength Index (RSI) | 52.47 |
| Average Volume (20 Days) | 685,871 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -208.57M |
| Net Income | -208.02M |
| EBITDA | -207.97M |
| EBIT | -207.97M |
| Earnings Per Share (EPS) | -0.56 |
Full Income StatementBalance Sheet
The company has 89.42M in cash and 0 in
debt, giving a net cash position of 89.42M.
| Cash & Cash Equivalents | 89.42M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -972.43M |
| Total Assets | 569.78M |
| Working Capital | 499.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -157.41M
and capital expenditures 0, giving a free cash flow of -157.41M.
| Operating Cash Flow | -157.41M |
| Capital Expenditures | n/a |
| Free Cash Flow | -157.41M |
| FCF Per Share | -0.42 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
